news
Neoadjuvant nivolumab improves long-term survival for lung cancer
Analysis of a Phase II trial for non-small cell lung cancer has suggested neoadjuvant nivolumab improved five-year recurrence-free survival compared with historical outcomes.
List view / Grid view
Memorial Sloan Kettering Cancer Center (MSK)
news
CAR T-cell therapy offers substantial remission rates in trial
In a Phase III study, a CAR T-cell therapy more than tripled progression-free survival compared with standard care for triple-class exposed multiple myeloma.
news
Alternative immunotherapies improve relapsed myeloma survival
Alternative CAR-T and cell therapies increased relapsed multiple myeloma patient survival by 18 months after failed CAR-T, a study found.
news
AstraZeneca dual immunotherapy approved for US liver cancer patients
The FDA has approved Imfinzi™ combined with Imjudo for adults with unresectable liver cancer, based on a lower risk of death compared to only sorafenib.
news
Erleada drug combination extends progression-free survival in prostate cancer trial
In the Phase III ACIS study, prostate cancer patients treated with a combination of Erleada® and Zytiga® plus prednisone were less likely to die than participants receiving Zytiga and prednisone.
news
Common cancer treatments do not worsen COVID-19 infection, study finds
A study has found that chemotherapy and surgery do not correlate with worse COVID-19 outcomes for cancer patients, whereas taking immune checkpoint inhibitors does.
news
Insight into 2020’s clinical trials landscape
Oncology, industry-sponsored and a combination of the two, will account for the majority of clinical trials categories over the course of the coming year.
news
Blood test predicts treatment response for metastatic prostate cancer
Testing could lead to extension of life through improved clinical decision-making by identifying patients who need to switch from targeted hormonal therapy to chemotherapy...
